1M6MYTD1A5AMAX
Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 109,81 € (+23,11 %). La mediana es de 108,94 € (+22,13 %).
| Comprar |
11 |
| Mantener |
3 |
| Vender |
0 |
Noticias Ir al feed de noticias
Monopar names head of Medical Affairs and reports ALXN1840 presentations at liver congress
Monopar appoints Dr. Jeffrey D. Kent as of September 1, 2026, to executive vice president and head of Medical Affairs. Two abstracts on ALXN1840, the late-stage development program for the treatment of Wilson disease, were accepted for presentations at AASLD “The Liver Meeting 2026,” including an oral presentation of the phase 3 results on November 8. ALXN1840 met the primary endpoint of copper mobilization over 48 weeks in the approval-relevant phase 3 study. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | 0 | - |
| Beneficio neto | -4,66 M | 123,65 % |
| EBITDA | -4,66 M | 123,65 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 632,39 M € |
Número de acciones | 6,7 M |
Máximo/mínimo de 52 semanas | 108,78 € - 40,86 € |
| Dividendos | No |
Beta | 1,50 |
Ratio P/E | -46,29 |
Ratio PEG | 1,62 |
Ratio P/B | 7,07 |
Ratio P/S | 0,00 |
Perfil de la empresa
| Nombre | Monopar Therapeutics Inc |
| CEO | Chandler D. Robinson |
| Empleados | 22 |
